module.exports = [
    {
        articleID: "902082",
        componentNumber: null, 
        slidePath: "902/082",
        rawSlides: `<p>&lt;&lt;insert slide 1; Chapter Title: Introduction; 00:00 &gt;&gt;  </p>

        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; VTE in Cancer: What Do the Latest Data Suggest?</strong></p>
        
        <p>&lt;&lt;insert slide 2; Chapter Title: Cancer and VTE Risk; 00:52 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; Risk of Cancer-Associated VTE</strong><sup>[1-4]</sup> </p>
        
        &#8226; Risk of venous thromboembolism (VTE) is elevated in cancer
        
        &#8226; In general, patients with cancer have a 1:5 chance of developing VTE
        
        &#8226; VTE risk is variable and dependent on a number of factors, including
        
        <tt>o   </tt>Cancer type (site of tumor)
        
        <tt>o   </tt>Cancer stage
        
        <tt>o   </tt>Time since diagnosis of cancer
        
        <tt>o   </tt>Cancer treatment
        
        <p>&lt;&lt;insert slide 3: 01:12 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; Risk Factors for Cancer-Associated VTE: Cancer Site</strong><sup>[4]</sup> </p>
        
        &#8226; The predominant risk factor is the location of the primary tumor
        
        &#8226; Overall, gastrointestinal (GI), pancreas, brain, lung, and ovarian cancer induce the highest risks
        
        &#8226; Relatively lower risks are seen in patients with breast or prostate cancer
        
        <p>&lt;&lt;insert slide 4: 02:27 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; Risk Factors for Cancer-Associated VTE: Cancer Treatment Modality</strong><sup>[5]</sup> </p>
        
        <p>&lt;&lt;insert slide 5: 04:25 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; Risk Factors for Cancer-Associated VTE: Patient-Related Factors</strong><sup>[5]</sup> </p>
        
        &#8226; Ethnicity
        
        <tt>o   </tt>Risk greater with African American vs Caucasian vs Asian population
        
        <tt>o   </tt>Attributed risk, however, is minor
        
        &#8226; Compression of major vessels by tumors
        
        <p>&lt;&lt;insert slide 6; Chapter Title: LMWH for VTE Treatment; 05:18 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; Guideline Recommendations: Cancer-Associated VTE Treatment</strong><sup>[6-8]</sup> </p>
        
        &#8226; Most guidelines recommend monotherapy with low-molecular-weight heparin (LMWH) for at least 6 months
        
        &#8226; Latest data from VTE treatment trials with non-vitamin K antagonist oral anticoagulants (NOACs) are challenging the current treatment paradigm
        
        <p>&lt;&lt;insert slide 7: 06:54 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; Challenges With LMWH</strong></p>
        
        &#8226; LMWHs are injectable agents
        
        <tt>o   </tt>Injectable agents are treated differently in prescription plans and copayment can be high
        
        <tt>o   </tt>Daily self-injection adds to the burden of treatment
        
        <p>&lt;&lt;insert slide 8: 07:32 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; Persistence With Anticoagulation for Cancer-Associated VTE</strong><sup>[9]</sup> </p>
        
        &#8226; Real-world analysis: LMWH was associated with significantly lower persistence and shorter duration of treatment
        
        <p>&lt;&lt;insert slide 9: 08:33 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; VTE and Major Bleeding Risk in Patients Receiving Chemotherapy: A Real-World Analysis</strong><sup>[10]</sup> </p>
        
        &#8226; Patients with cancer are at high risk of both VTE and major bleeding
        
        &#8226; VTE and major bleeding can be fatal
        
        &#8226; Major bleeding can be difficult to treat; especially GI mucosal bleeding
        
        &#8226; Minor (eg, nuisance) bleeding is also common
        
        <p>&lt;&lt;insert slide 10; Chapter Title: NOACS for VTE Treatment; 09:24 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; Treatment of Cancer-Associated VTE: Clinical Trials of NOACs</strong><sup>[11-13]</sup> </p>
        
        <p>&lt;&lt;insert slide 11: 10:36 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; Hokusai VTE-Cancer: Design</strong><sup>[14]</sup> </p>
        
        &#8226; Study population with active cancer and symptomatic/incidental deep vein thrombosis (DVT) or proximal pulmonary embolism (PE)
        
        <tt>o   </tt>DVT of proximal lower extremity (popliteal, femoral, or iliac vein thrombosis)
        
        <tt>o   </tt>PE involving segmental or more proximal pulmonary arteries
        
        &#8226; All patients were treated for at least 6 months
        
        &#8226; Physicians were encouraged to continue treatment for 12 months
        
        <p>&lt;&lt;insert slide 12: 11:45 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; Hokusai VTE-Cancer: Primary Outcome</strong><sup>[11]</sup> </p>
        
        &#8226; Edoxaban was noninferior to dalteparin
        
        <p>&lt;&lt;insert slide 13: 12:05 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; Hokusai VTE-Cancer: Primary Outcome Components</strong><sup>[11]</sup> </p>
        
        &#8226; Rate of recurrent VTE was significantly lower with edoxaban vs dalteparin
        
        &#8226; Rate of major bleeding was significantly higher with edoxaban vs dalteparin
        
        &#8226; Most major bleeding occurred in patients with GI cancers
        
        <p>&lt;&lt;insert slide 14: 13:11 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; SELECT-D: Design</strong><sup>[15]</sup> </p>
        
        &#8226; Study population similar to Hokusai VTE-Cancer
        
        <p>&lt;&lt;insert slide 15: 13:37 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; SELECT-D: Primary Endpoint &#8211; Recurrent VTE at 6 Months</strong><sup>[12]</sup> </p>
        
        &#8226; Rivaroxaban was associated with relatively low VTE recurrence compared with dalteparin
        
        <p>&lt;&lt;insert slide 16: 13:48 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; SELECT-D: Major and CRNM Bleeding at 6 Months</strong><sup>[12]</sup> </p>
        
        &#8226; Rivaroxaban was associated with relatively higher clinically relevant nonmajor (CRNM) bleeding compared with dalteparin
        
        &#8226; Most of the major bleeding occurred in patients with GI cancers
        
        <p>&lt;&lt;insert slide 17: 15:01 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; SELECT-D: Major Bleeding by Tumor Type</strong><sup>[12]</sup> </p>
        
        &#8226; Among GI cancers, most major bleeding was confined to upper GI cancers
        
        <p>&lt;&lt;insert slide 18: 15:28 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; Hokusai VTE-Cancer: Major Bleeding by Tumor Type</strong><sup>[16]</sup> </p>
        
        &#8226; Excess major bleeding with edoxaban was confined to patients with GI cancer
        
        <p>&lt;&lt;insert slide 19; Chapter Title: Guidance on Use of NOACs; 16:38 &gt;&gt;</p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; NOACs for Treatment of Cancer Associated VTE: Guidance From ISTH</strong><sup>[17]</sup> </p>
        
        &#8226; An estimated 60% to 70% of overall cancer population may be eligible for treatment with NOACs
        
        &#8226; In patients with high risk of bleeding, reassess therapy options when bleeding risk changes over time
        
        &#8226; Patients with severe thrombocytopenia are candidates for LMWH
        
        <tt>o   </tt>LMWH can be dose-adjusted based on the platelet count
        
        <tt>o   </tt>Fine tuning of dose is not currently possible with NOACs
        
        <p>&lt;&lt;insert slide 20: 18:55 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; Anticoagulation in Cancer Patients With Thrombocytopenia: Guidance From ISTH</strong><sup>[18]</sup> </p>
        
        &#8226; Option to start with one therapy and switch to another when patient condition improves
        
        &#8226; For example, in patients with GI cancer
        
        <tt>o   </tt>Could start therapy with LMWH
        
        <tt>o   </tt>If bleeding risk improves, switch to a NOAC
        
        <tt>o   </tt>If platelet count declines after switching to NOAC, bridge to LMWH until platelet count improves to safely resume NOAC
        
        <p>&lt;&lt;insert slide 21; Chapter Title: VTE Prevention; 22:33 &gt;&gt;</p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; Guidance for Prevention of Cancer-Associated VTE</strong><sup>[19]</sup> </p>
        
        &#8226; Clinical trials on thromboprophylaxis found benefit in patients with high risk score (Khorana score &#8805;3)
        
        &#8226; Although thromboprophylaxis is recommended in patients with cancer who are at high risk of VTE, it is not usually followed
        
        <p>&lt;&lt;insert slide 22: 23:30 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; CASSINI: Design</strong><sup>[20]</sup> </p>
        
        <p>&lt;&lt;insert slide 23: 24:07 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; AVERT: Design</strong><sup>[21]</sup> </p>
        
        <p>&lt;&lt;insert slide 24; Chapter Title: Summary; 24:50 &gt;&gt;</p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; Summary</strong></p>
        
        <p>&lt;&lt;insert slide 25: 25:36 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; Summary (cont)</strong></p>
        
        <p>&lt;&lt;insert slide 26: 27:04 &gt;&gt;  </p>
        
        <p>
        
        <strong>&lt;&lt;Level 2&gt;&gt; Thank you</strong></p>`
    }
];